ORIGINAL RESEARCH article
Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1654251
This article is part of the Research TopicBiomarker Discovery and Validation in Neurological DiseasesView all 4 articles
The diagnostic and prognostic value of CXCL13, CXCL10, and CXCL8 in patients with neurosyphilis
Provisionally accepted- 1Department of Infectious Diseases, The School of Public Health of Nanjing Medical University, The Second Hospital of Nanjing, Jiangsu,Nanjing, China
- 2Department of Infectious Diseases, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Jiangsu,Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background The purpose of this study is to examine the diagnostic and therapeutic value of CXCL13 (CSF-CXCL13), CXCL10 (CSF-CXCL10), and CXCL8 (CSF-CXCXCL8) in NS patients in a systematic manner. Method The study will include individuals who are the first to undergo neurosyphilis (NS) screening from August 2023 to October 2024, and will gather demographic, clinical, and laboratory data, as well as cerebrospinal fluid (CSF) and blood samples. Enzyme-linked immunosorbent assay (ELISA) was used to quantitatively detect the concentrations of CXCL13, CXCL10, and CXCL8 in CSF and blood samples.Use receiver operating characteristic (ROC) curves to evaluate the ability of cytokines to distinguish between NS and non-NS individuals, and further evaluate in different populations, including the total population ,People Living with HIV(PLWH) , Non-People Living with HIV(Non-PLWH) population. Develop an NS diagnostic model using logistic regression analysis results, and ensure the model is valid by conducting 5-fold cross-validation, calibration curve, and clinical decision curve (DCA). Use a Nomogram to visualize the model. Result A total of 233 participants were included in the study.ROC shows that the area under the curve (AUC) of CSF-CXCL13 in distinguishing NS from Non-NS 、NS from CNS infections is 0.812 and 0.839, respectively. In contrast, the AUC of CSF-CXCL10 and CSF-CXCL8 in distinguishing NS from Non-NS were 0.568 and 0.638, respectively.The AUC in distinguishing NS from other CNS infections were 0.604 and 0.556, respectively. To enhance the effectiveness of differential diagnosis, we employed logistic regression analysis to screen variables and developed a predictive model MODEL1. The results showed that the AUC value of MODEL1 was 0.888, and the calibration curve and DCA curve demonstrated good accuracy and clinical benefits of the model, demonstrating good predictive performance. After NS treatment, the levels of CSF-CXCL13, CSF-CXCL10, and CSF-CXCL8 slightly decreased. Conclusion CSF-CXCL13 has good differential value in distinguishing NS from Non-NS, NS from CNS infections, while CSF-CXCL10 and CSF-CXCL8 have lower differential sensitivity. The diagnostic performance of the NS diagnostic model (Model 1) based on CSF-CXCL13 has been improved.
Keywords: Neurosyphilis, CXC chemokine ligand 13, HIV, diagnosis, Model construction
Received: 26 Jun 2025; Accepted: 08 Oct 2025.
Copyright: © 2025 Hongjing, Ping, Zihao, Xiaoyun, Qin, Chunmiao, Rentian, Chen and Hongxia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Hongxia, wghongxia@sina.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.